Supplemental Table S8. Evidence linking *CYP2C19* genotype with phenotype (CLOPIDOGREL DOSE ESCALATION)

Study Endpoints	Major Findings	References	Level of Evidence*
Ex vivo platelet aggregation	Higher-dose clopidogrel can increase the degree of platelet inhibition in healthy subjects heterozygous for *CYP2C19* LOF alleles	Simon, *et al*. 2011 (57)	High
Ex vivo platelet aggregation	Higher-dose clopidogrel can increase the degree of platelet inhibition in patients heterozygous for *CYP2C19* LOF alleles but less so in patients homozygous for LOF alleles	Gladding, *et al*. 2008 (154), Gladding, *et al*. 2009 (40), Barker, *et al*. 2010 (155), Bonello, *et al*. 2010 (156), Alexopoulos, *et al*, 2011 (157), Collet, *et al*. 2011 (114), Cuisset, *et al*. 2011 (122), Mega, *et al*. 2011 (158)	High
Clinical: composite end point of cardiovascular death, MI and ST	Higher dose clopidogrel on the basis of platelet function monitoring does not result in clinical benefit among ACS/PCI patients.	Price, *et al*. 2011 (159), Collet, *et al*. 2012 (160)	High

ACS: acute coronary syndrome; LOF: loss-of-function; PCI: percutaneous coronary intervention.
***** See above for description of '**Levels of Evidence Linking Genotype to Phenotype**'